Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

Phase: N/A Priority: Normal
NCT ID: NCT01161914 Org: User:
Start: 01/31/11 End: - Due: -

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03552406 Org: User:
Start: 04/27/18 End: 12/31/21 Due: 12/31/22

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Phase: N/A Priority: Normal
NCT ID: NCT03186677 Org: User:
Start: 06/03/17 End: 02/22/19 Due: 02/22/20

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04787887 Org: User:
Start: 01/29/20 End: 10/26/20 Due: 10/26/21

Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients

Phase: N/A Priority: Normal
NCT ID: NCT03087539 Org: User:
Start: 05/31/13 End: 06/30/17 Due: 06/30/18

Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

Phase: N/A Priority: Normal
NCT ID: NCT02770625 Org: User:
Start: 09/30/11 End: 08/31/14 Due: 08/31/15

A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

Phase: N/A Priority: Normal
NCT ID: NCT02053896 Org: User:
Start: 05/31/11 End: 02/29/12 Due: 02/28/13

Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT06081062 Org: User:
Start: 04/14/23 End: 12/31/25 Due: 12/31/26

A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01881633 Org: User:
Start: 10/31/10 End: 11/30/10 Due: 11/30/11